Literature DB >> 31591448

Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation.

Seug Yun Yoon1, Jae-Ho Yoon1, Gi June Min1, Sung-Soo Park1, Silvia Park1, Sung-Eun Lee1, Byung-Sik Cho1, Ki-Seong Eom1, Yoo-Jin Kim1, Hee-Je Kim1, Chang-Ki Min1, Seok-Goo Cho1, Jong Wook Lee1, Seok Lee2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31591448     DOI： 10.1038/s41409-019-0708-9

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Authors:  Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp
Journal:  N Engl J Med       Date:  2017-03-02       Impact factor: 91.245

2.  Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.

Authors:  Albert Oriol; Susana Vives; Jesús-María Hernández-Rivas; Mar Tormo; Inmaculada Heras; Concepción Rivas; Concepción Bethencourt; Federico Moscardó; Javier Bueno; Carlos Grande; Eloy del Potro; Ramon Guardia; Salut Brunet; Juan Bergua; Teresa Bernal; Maria-José Moreno; Carlota Calvo; Pilar Bastida; Evarist Feliu; Josep-Maria Ribera
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

3.  Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.

Authors:  Ibrahim Aldoss; Joo Song; Tracey Stiller; Tina Nguyen; Joycelynne Palmer; Margaret O'Donnell; Anthony S Stein; Guido Marcucci; Stephen Forman; Vinod Pullarkat
Journal:  Am J Hematol       Date:  2017-06-05       Impact factor: 10.047

4.  How I treat extramedullary acute myeloid leukemia.

Authors:  Richard L Bakst; Martin S Tallman; Dan Douer; Joachim Yahalom
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

5.  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Authors:  Nicola Gökbuget; Hervé Dombret; Massimiliano Bonifacio; Albrecht Reichle; Carlos Graux; Christoph Faul; Helmut Diedrich; Max S Topp; Monika Brüggemann; Heinz-August Horst; Violaine Havelange; Julia Stieglmaier; Hendrik Wessels; Vincent Haddad; Jonathan E Benjamin; Gerhard Zugmaier; Dirk Nagorsen; Ralf C Bargou
Journal:  Blood       Date:  2018-01-22       Impact factor: 22.113

6.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

Authors:  Nicola Gökbuget; Daniel Stanze; Joachim Beck; Helmut Diedrich; Heinz-August Horst; Andreas Hüttmann; Guido Kobbe; Karl-Anton Kreuzer; Lothar Leimer; Albrecht Reichle; Markus Schaich; Stefan Schwartz; Hubert Serve; Michael Starck; Matthias Stelljes; Reingard Stuhlmann; Andreas Viardot; Knut Wendelin; Mathias Freund; Dieter Hoelzer
Journal:  Blood       Date:  2012-04-04       Impact factor: 22.113

7.  Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

Authors:  B-S Cho; S Lee; Y-J Kim; N-G Chung; K-S Eom; H-J Kim; C-K Min; S-G Cho; D-W Kim; J-W Lee; W-S Min; C-C Kim
Journal:  Leukemia       Date:  2009-05-14       Impact factor: 11.528

8.  Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.

Authors:  Ki-Seong Eom; Seung-Hwan Shin; Jae-Ho Yoon; Seung-Ah Yahng; Sung-Eun Lee; Byung-Sik Cho; Yoo-Jin Kim; Hee-Je Kim; Chang-Ki Min; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chong-Won Park; Seok Lee
Journal:  Am J Hematol       Date:  2013-05-30       Impact factor: 10.047

9.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.

Authors:  E Tavernier; J-M Boiron; F Huguet; K Bradstock; N Vey; T Kovacsovics; A Delannoy; N Fegueux; P Fenaux; A Stamatoullas; O Tournilhac; A Buzyn; O Reman; C Charrin; C Boucheix; J Gabert; V Lhéritier; J-P Vernant; H Dombret; X Thomas
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528

10.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.

Authors:  Adele K Fielding; Susan M Richards; Rajesh Chopra; Hillard M Lazarus; Mark R Litzow; Georgina Buck; I Jill Durrant; Selina M Luger; David I Marks; Ian M Franklin; Andrew K McMillan; Martin S Tallman; Jacob M Rowe; Anthony H Goldstone
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113
View more
  2 in total

1.  Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy.

Authors:  Joonyeop Lee; Jae-Ho Yoon; Daehun Kwag; Jong-Hyuk Lee; Tong Yoon Kim; Gi June Min; Sung-Soo Park; Silvia Park; Sung-Eun Lee; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Hee-Je Kim; Chang-Ki Min; Seok-Goo Cho; Jong Wook Lee; Sung Hak Lee; Seok Lee
Journal:  Ther Adv Hematol       Date:  2021-12-21

2.  Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation.

Authors:  Hengwei Wu; Zhen Cai; Jimin Shi; Yi Luo; He Huang; Yanmin Zhao
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.